Chimeric antigen receptor (CAR) T cell therapy has been highly successful in hematological
malignancies leading to their US Food and Drug Administration (FDA) approval. However, …

FLT3-ITD mutations are common in AML and are associated with poor prognosis. We show
that FLT3-ITD stimulates serine biosynthesis, thereby rendering FLT3-ITD–driven leukemias …

Peripheral T-cell lymphoma (PTCL) is a rare, heterogenous malignancy with dismal outcomes
at relapse. Hypomethylating agents (HMA) have an emerging role in PTCL, supported by …

Cytosine analog hypomethylating agents (HMAs) constitute one of the few approved life-prolonging
therapies for myelodysplasia (MDS) and acute myeloid leukemia (AML) in patients …

Targeted inhibitors of bromodomain and extraterminal (BET)-bromodomains and
phosphatidylinositol-3-kinase (PI3K) signaling demonstrate potent but self-limited antilymphoma …

Approximately 20% of acute myeloid leukemia (AML) patients carry mutations in IDH1 or
IDH2 that result in over-production of the oncometabolite D-2-hydroxyglutarate (2-HG). Small …

The dendritic cell receptor Clec9A facilitates processing of dead cell-derived antigens for
cross-presentation and the induction of effective CD8 + T cell immune responses. Here, we …

The mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) catalyzes one of the
rate‐limiting steps in de novo pyrimidine biosynthesis, a pathway that provides essential …

Estrogen receptor-positive breast cancers (ER + BCas) are the most common form of BCa
and are increasing in incidence, largely due to changes in reproductive practices in recent …

Constraint-based optimization, such as flux balance analysis (FBA), has become a standard
systems-biology computational method to study cellular metabolisms that are assumed to …